Background-The relations between chronic kidney disease (CKD) and incident heart failure remain unclear. Methods and Results-We related CKD to incident nonfatal heart failure and cardiovascular (CVD) death (as separate and combined end points) in 10 181 male participants (mean age, 67 years). Kidney function was assessed by estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease equation in clinically relevant categories of Ͻ60 and Ն60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 (referent) and Ͻ45, 45 to 60, 60 to 90, and Ն90 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 (referent). During follow-up (mean, 10.1 years; range, 0.03 to 12.2), 439 developed heart failure and 832 had CVD death/heart failure. In multivariable models, men with eGFR Ͻ60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 had a 2-fold risk of heart failure (95% confidence interval, 1.62 to 2.56, PϽ0.0001) compared with referent category. The hazard ratio (with corresponding 95% confidence interval) for development of heart failure according to eGFR categories of 60 to 90, 45 to 60, and Ͻ45 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 compared with referent category were 1.24 (0.98 to 1.56), 2.58 (1.91 to 3.49), and 1.52 (0.92 to 2.76), respectively. In the analyses restricted to subgroup of nondiabetic individuals and normotensive individuals at baseline (nϭ7545), men with eGFR Ͻ60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 had a 2.2-fold risk of heart failure (95% confidence interval, 1.66 to 2.95), compared with men with eGFR Ն60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 . Additionally, risk of heart failure or CVD death was Ͼ2.5-fold higher among individuals with eGFR 45 to 60 and Ͻ45 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 , compared with referent category. Conclusions-Moderate level of CKD, even in absence of diabetes and hypertension at baseline, is associated with a higher risk of development of heart failure and CVD death/heart failure in men. (Circ Heart Fail. 2011;4:138-144.)
C ompared with those who have end-stage renal failure, individuals with mild-to-moderate kidney disease have a higher risk of cardiovascular disease (CVD). 1 Epidemiological definition of CVD 2 includes "heart failure," though the mechanisms of development of heart failure are not well established. 3 Heart failure is increasing in prevalence and incidence, with an average middle-aged individual having 1 in 5 chances of having heart failure in his or her lifetime. 4 
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Cross-sectionally, individuals with mild-to-moderate kidney disease have a higher prevalence of left ventricular hypertrophy (LVH)-a precursor for heart failure. 5 In fact, data from US National Kidney Foundation estimated that 75% of individuals have LVH at the time of dialysis initiation. 6 In longitudinal studies, few investigators have separately evaluated the risk of heart failure according to different markers of renal function in selected individuals (ie, older individuals). [7] [8] [9] [10] [11] In addition, prior epidemiological studies evaluating the association between chronic kidney disease (CKD) and CVD (including heart failure) have shown conflicting results, with most reporting a significantly increased risk of CVD in CKD patients, 12, 13 whereas some observed no association of CKD to incident CVD in the community. 14, 15 Moreover, data from NHANES shows a lack of association between proteinuria (a marker of early renal disease) and incident heart failure. 16 Overall, it remains unanswered whether there is any increased risk of heart failure in those with mild-to-moderate renal dysfunction. 1 Therefore, in the present investigation, we evaluated the relations of estimated glomerular filtration rate (eGFR) to the incidence of heart failure in the Physicians' Health Study (PHS) participants who were free of heart failure and myocardial infarction (MI) at baseline. As a secondary aim, we analyzed if the association of CKD to incident heart failure is influenced by prevalent diabetes and hypertension by excluding participants with diabetes and hypertension at baseline. Additionally, we also evaluated the relations of CKD to CVD death or incident heart failure as a combined end point.
Methods

Study Participants
The design and selection criteria for the PHS have been described previously. 17 Briefly, 22 071 apparently healthy male physicians without a history of cardiovascular disease, cancer, or liver or kidney disease were enrolled in this study. Between 1995 and 2000, all current participants (nϭ14 642) were asked to provide a blood sample by mail. For the present investigation, we selected individuals with available information on measured levels of serum creatinine (nϭ11 105). A simplified version of the Modification of Diet in Renal Disease equation was used to calculate the eGFR. 18 We excluded participants who reported heart failure at baseline or did not report any information about heart failure at the time of blood collection on their annual questionnaire (nϭ224), participants with a history of MI (nϭ375), and those with missing covariates (nϭ325); therefore, for the present study, our final sample included 10 181 participants. There were no significant differences between participants who provided a blood sample from those who did not. Additionally, participants with missing covariates were similar in characteristics to those with all information available (data not shown). All participants signed informed consent, and the protocol for study was approved by Institutional Review Board of Brigham and Women's Hospital.
Measurement of Risk Factors
All information on demographics, medical history including history of diabetes mellitus, hypertension, heart failure, and other lifestyle variables were obtained annually. Therefore, information on body weight, presence or absence of diabetes mellitus, blood pressure, smoking habits, alcohol consumption, exercise routine, any use of anticholesterol medications, and interim MI were obtained by questionnaires. Body mass index (BMI) was calculated by dividing weight in kilograms by height in meters squared. Alcohol consumption was ascertained by calculating the average number of drinks consumed in categories of rarely or never, 1 to 3/mo, Ն1/wk, and Ն1/d. Smoking history was reported in categories of never-smokers, former smokers, and current smokers.
Medical records from Ͼ95% of participants were obtained after each self-reported nonfatal MI and on receipt of their consent or consent from their next of kin (in case of death) after a fatal MI. Thereafter, an end point committee (by using World Health Organization criteria) 19 confirmed all MI diagnoses by inspection of medical records and other available information.
Participants reported physical activity to a point of breaking into sweat and were categorized into Ͻ1 d/wk (referent), 1 to 3 d/wk, 3 to 4 d/wk, and 5 to 7 d/wk. In the present study, hypertension was present on the basis of self-reported blood pressure of Ն140 mm Hg systolic or Ն90 mm Hg diastolic or history of hypertension or if on antihypertensive medications.
Blood Collection and Measurement of Serum Creatinine
On receipt of all EDTA blood specimens in the mail, samples were centrifuged, divided into aliquots, and frozen. Measurement of serum creatinine was performed in Oxford, England, using the Jaffe technique by a Synchronon LX20 autoanalyzer (Beckman Coulter, Fullerton, CA) as previously described. 20 Coefficient of variation for blinded duplicate samples was 7.1%, and intrabatch variations ranged from 1.4% to 2.3%.
Ascertainment of Heart Failure and CVD Death
Information on heart failure was collected through self-reports from participants on the annual PHS questionnaire. We examined the validity of these self-reported heart failure events in a subset of 88 alive, randomly selected cases who had reported recent new episodes of heart failure. These selected individuals were mailed a question-naire to obtain additional information on their symptoms, signs, and laboratory investigations performed at the time of presentation with heart failure. After 2 mailings and further follow-ups by telephone, all collected information was reviewed to verify a diagnosis of heart failure based on Framingham heart failure criteria. 21 Of the 88 self-reported heart failure cases, 76 (86%) returned their completed questionnaires. Overall, we successfully confirmed heart failure in 68 (89%) individuals, which suggested reasonably high validity for an epidemiological study as described earlier. 22 Additionally, a separate validation using information on invasive and other noninvasive imaging modalities to ascertain the diagnosis of heart failure for this sample of individuals showing 91% accuracy has also been published elsewhere. 23 All deaths attributed to CVD were confirmed by an end point committee using information from death certificates, next of kin, and medical records and have been published in detail previously. 24 
Statistical Analyses
Baseline characteristics of the participants were assessed according to eGFR of Ͻ60 and Ն60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 . We estimated the cumulative incidence of heart failure per 1000 person-years in each category of eGFR. We also constructed cumulative incidence curves using the Kaplan-Meier method according to eGFR categories. Assumptions for proportional hazard models were tested by fitting a product term eGFRϫlog (person-time of follow-up), and we found no evidence of violation (Pϭ0.18). Then, after confirming that the assumption of proportionality of hazards was met, we used Cox regression models to relate eGFR levels to the incidence of heart failure. eGFR was analyzed in categories of Ͻ60 and Ն60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 (referent) and Ͻ45, 45 to 60, 60 to 90, and Ն90 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 (referent). All multivariable models were adjusted for age (as part of eGFR calculation), BMI, systolic and diastolic blood pressure, diabetes mellitus, smoking history, alcohol intake, and physical activity (exercise per week). We chose not to adjust for serum cholesterol or treatment of cholesterol because in the PHS data set, serum cholesterol levels have not been associated with incident heart failure. 22 We assessed for any effect modification by hypertension, diabetes, and BMI using interaction terms in multivariable models adjusting for all covariates (as above) to assess the risk of heart failure according to eGFR categories of Ͻ60 and Ն60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 .
Subgroup Analyses
In subgroup analyses, we excluded all participants with diabetes mellitus (nϭ599) and hypertension at baseline (nϭ2037) and additionally adjusted for diabetes mellitus, hypertension, and MI as time-dependent covariates (in addition to other covariates as described above for primary analyses). These subgroup analyses were performed because individuals with hypertension and diabetes are highly predisposed to have CKD and heart failure. We did not have enough events for separate analysis in subjects with diabetes or hypertension.
Additional Analyses
Because a fatal heart failure end point was not available in our data set, we examined the combined risk of heart failure and CVD death (whichever came first), according to renal function categories. We estimated the cumulative incidence of CVD death or heart failure per 1000 person-years, constructed cumulative incidence curves, and examined the relations of CKD to CVD death or heart failure using Cox regression models, adjusting for all variables as in our primary analyses (see above) according to each category of eGFR.
All analyses were performed using SAS 9.2 (Cary, NC) software. A 2-sided probability value of Ͻ0.05 was considered statistically significant. Table 2) . Cumulative incident curves (truncated to Յ10 years) demonstrated a graded increase in incidence of heart failure according to different categories of eGFR (log-rank PϽ0.0001 for both curves; Figure 1 and Figure 2) . Notably, those with eGFR between 45 to 60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 showed graded and lowest survival rates compared with other categories ( Figure 2 ). In multivariable models, individuals with eGFR Ͻ60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 had Ͼ2-fold and those with eGFR between 45 and 60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 had Ͼ2.5-fold higher risk of heart failure (hazard ratio [HR], 2.58; 95% confidence interval [CI], 1.91 to 3.48; Table 3 ) Values are meanϮstandard deviation or otherwise indicated. when compared with referent categories. Further, when age was included as a variable (in addition to using age in calculation of eGFR) in multivariable models, the risk of heart failure was attenuated; however, it remained statistically significant for individuals with eGFR between 45 to 60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 (HR, 1.45; 95% CI, 1.07 to 1.97). The risk of heart failure was attenuated and was not statistically significant in individuals with eGFR Ͻ45 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 , perhaps because there were fewer individuals in that category compared with referent category (Table 3) . Additionally, when we excluded men with eGFR Ͻ30 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 (nϭ44; 3 heart failure events), the risk of heart failure was further attenuated among those with eGFR Ͻ45 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 (HR, 1.49; 95% CI, 0.80 to 2.78; Pϭ0.21). We could not detect any effect modification by hypertension, diabetes, or BMI when heart failure risk was evaluated for individuals with eGFR Ͻ60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 compared with the referent category (all probability values Ͼ0.10).
Results
Subgroup Analyses
In the subgroup of individuals without diabetes and hypertension at baseline, 532 individuals had diabetes, 2424 had hypertension, 398 had interim MI, and 284 participants had heart failure on follow-up. Cumulative incident rates per 1000 person-years of follow-up were similar to that of the entire sample ( Table 2 ). In multivariable models with adjustment for all covariates including diabetes, hypertension, and MI as time-dependent variables, the risk of heart failure remained robust, with Ͼ2.0-fold among individuals with eGFR Ͻ60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 and Ͼ2.5-fold for those with eGFR between 45 to 60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 , compared with the respective referent categories ( Table 2 ). The risk of heart failure in individuals with eGFR Ͻ45 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 was statistically significant and almost reached 2-fold, compared with the referent category.
Additional Analyses
Because we did not have information on fatal heart failure events, we also examined the relations of eGFR categories to the incidence of heart failure and CVD death as a combined end point. There were 832 combined events on follow-up (mean, 10 years). Cumulative incidence curves showed graded increasing risk (Figure 3 ), and incident rates increased Table 3 ). These associations remained robust and were slightly attenuated after excluding men with diabetes and hypertension at baseline (Table 3) . Last, CVD death or new-onset heart failure was Ͼ2-fold higher among individuals with eGFR Ͻ60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 , even in the subgroup of normotensive and nondiabetics, compared with the referent category.
Discussion
Principal Findings
Our primary results were 3-fold. First, in individuals who were free of heart failure at baseline, eGFR between 45 to 60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 was associated with higher risk of heart failure on follow-up. Categorical models showed approximately 2-to 2.5-fold higher risk of heart failure in individuals within this category, although in the multivariable models, age was a confounder of the association between CKD and heart failure risk. Second, the subgroup of nondiabetic and normotensive men with eGFR between 45 to 60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 had the greatest risk of developing new-onset heart failure. Third, among individuals with eGFR Ͻ45 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 and those with eGFR 45 to 60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 , the risk of CVD death or heart failure was Ͼ2.5-fold compared with the referent category and was attenuated minimally with exclusion of diabetics and normotensive individuals at baseline.
Comparison With Prior Literature
Prior results from 2 large, epidemiological studies did not show any increased risk of heart failure with higher serum creatinine, 14,15 but others have observed higher risk of heart failure with increasing serum creatinine levels 9 -11 and with lower eGFR. 8, 12, 13 Recently, newer but costlier markers such as cystatin C have been studied to measure kidney function decline in assessment of heart failure risk 25 ; researchers have observed differences by race and blood pressure such that blacks were at higher risk compared with white individuals 7 and hypertensive individuals were more prone to have heart failure compared with normotensive individuals. 26
Mechanisms
There are several possible mechanisms that can increase the risk of heart failure in individuals with CKD. First, as postulated earlier, individuals with CKD have higher prevalence of hypertension, diabetes mellitus, higher BMI, and other coronary risk factors that are also known to increase the risk for heart failure. Moreover, many researchers evaluating the risk of CVD in CKD patients have also postulated that most of the CVD risk probably is due to higher prevalence of traditional coronary risk factors in CKD patients. 14, 15, 27 In the present study, however, the risk of heart failure in participants with eGFR Ͻ60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 was maintained after adjustment for traditional risk factors. Subgroup analyses also revealed that there was no difference when the risk for heart failure was evaluated among nondiabetic and normotensive individuals with adjustment for MI on follow-up. Second, damage to nephrons in renal dysfunction leads to high blood pressure through mechanisms such as plasma volume expansion, overactivity of the sympathetic nervous system, and the renin-angiotensin-aldosterone axis, 28 which sets a vicious circle of higher blood pressure thereby leading to left ventricular enlargement, 29 a known precursor for heart failure. 30 A regression of hypertrophy is associated with reduced cardiac failure outcomes. 31 Of note, a tighter control of blood pressure is also known to decrease the progression of kidney disease in some but not all studies. 32 However, in the present study, nondiabetic and normotensive individuals with moderate to severe kidney disease exhibited similar and higher risk of heart failure compared with the entire sample, independent of having hypertension on follow-up.
Third, moderate to advanced kidney disease is associated with higher serum phosphorus, which is further linked to development of LVH in experimental studies 33, 34 and higher incidence of CVD mortality in some 35, 36 but not all 37 epidemiological studies. However, recent data also suggest that a high but "normal" level of serum phosphorus is associated with greater risk of development of CVD (including heart failure) in the community. 38 Therefore, it is plausible that mild to moderate CKD may lead to elevated serum phosphorus, which then can lead to an increased risk for the development of LVH and clinical heart failure.
Last, patients with CKD have decreased erythropoietin formation, which leads to development of anemia. A graded decrease in hemoglobin concentration is significantly associated with increases in left ventricular mass. 39 Conversely, even partial correction of anemia in dialysis patients has been shown to produce regression of LVH. 40 
Strengths and Limitations
The present study has the largest sample size, including a large subgroup of nondiabetic individuals and normotensive individuals, as compared with previous studies. In the present analyses, we accounted for all traditional coronary risk factors as well as CHD, diabetes, and hypertension on follow-up, which strengthens our study. Some limitations also merit discussion. First, measurement of renal function based on different formulas to measure eGFR has been questioned, and some have found novel markers such as cystatin C to be better predictors of renal dysfunction 25 ; however, eGFR remains the least expensive and more precise method of measuring kidney function. 41 CKD is defined by the National Kidney Foundation as eGFR Ͻ60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 for a period of at least 3 months. In the present study (and perhaps in most other large epidemiological studies), a single measurement is often used. Moreover, any misclassification in the present study probably would underestimate the relations and would bias results toward the null. It is plausible that the risk of heart failure and CVD death may vary with time, especially in individuals with impaired kidney function. Second, in our data set, we did not have information on fatal heart failure events; therefore, we performed additional analyses using CVD death or heart failure as a combined event. Individuals within eGFR categories of 45 to 60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 and Ͻ45 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 had a statistically significant higher risk of combined event (heart failure and CVD death). Of note, the hazard ratio for incident CVD death is even higher among men with eGFR Ͻ45 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 compared with those with eGFR between 45 to 60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 . Therefore, it is plausible that individuals in the category of eGFR Ͻ45 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 had more first fatal heart failure episodes. However, data from US renal data system indicates that only 13% of CVD deaths are associated with heart failure, which also includes deaths among patients with chronic heart failure. 42 Last, participants in our study were predominantly white men who were physicians; hence, results may have limited generalizability for women and may differ with socioeconomic class.
Conclusion
In this sample of men free of heart failure at baseline, moderate CKD was associated with a higher incidence of heart failure and CVD death or heart failure on follow-up. Additionally, a subgroup of normotensive and nondiabetic individuals with moderate CKD also had a similar and higher risk of heart failure as for the whole sample.
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